CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

Summary

This phase Ib trial tests the safety, side effects and best dose of clustered regularly interspaced short palindromic repeats (CRISPR) delivered anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells (1XX BCMA CAR-T cells) in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Anti-BCMA CAR-T cell therapy is a type of treatment in which a person's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as BCMA, on the patient's cancer cells is added to the T cells in the laboratory by a tool called clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9. The special receptor is called a CAR. Large numbers of the CAR-T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving chemotherapy before CAR-T cells may decrease the number of lymphocytes (a type of white blood cells) in the blood and may help the 1XX BCMA CAR-T cells fight the cancer cells. Treatment with 1XX BCMA CAR-T cells may be safe, tolerable, and/or effective in treating patients with relapsed or refractory multiple myeloma (RRMM).

Conditions

• Multiple Myeloma
• Recurrent Multiple Myeloma
• Refractory Multiple Myeloma

Interventions

BIOLOGICAL

Biospecimen Collection

Undergo Blood, serum and urine collection

DRUG

Fludarabine

Given IV

PROCEDURE

Radiographic imaging

Undergo radiographic imaging

BEHAVIORAL

Quality of Life (QoL) Questionnaires

Ancillary studies

PROCEDURE

Leukapheresis

Undergo Leukapheresis

DRUG

Cyclophosphamide

Given Intravenously (IV)

BIOLOGICAL

Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA

Given Intravenously (IV)

PROCEDURE

Bone Marrow Biopsy

Undergo biopsy

Sponsors & Collaborators

• Thomas Martin, MD

  lead OTHER

Principal Investigators

• Thomas G Martin, MD · University of California, San Francisco

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-02-28

Primary Completion

2028-05-25

Completion

2043-05-25

FDA Drug

Yes

Countries

• United States

Study Locations